|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2015-4-11 14:11 编辑
Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
April 10, 2015 06:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies involving patients with chronic HBV infection who were treated with REP 2139-Ca in combination with immunotherapy and /or entecavir (ETV).
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor’s poster presentation will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For more information on the 2015 Lancet Viral Hepatitis Meeting: www.asianoncologysummit.com/vhep-summit.asp
About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.
Contacts
Replicor
Alexandra Peterson, 212-508-9709
[email protected]
Replicor将出席2015年柳叶刀病毒性肝炎会议
2015年4月10日上午06时东部夏令时间
纽约 - （BUSINESS WIRE） - Replicor公司，靶向治疗慢性乙型肝炎（HBV）和丁型肝炎一家私人持有的生物制药公司（HDV）感染，今天宣布，将目前最新的临床资料柳叶刀病毒性肝炎会议在中国上海从4月10-12日，2015年的数据是从涉及病人的慢性HBV感染者的研究谁是与REP 2139Ca与免疫治疗和/或恩替卡韦（ETV）联合治疗。
REP 2139Ca单独使用或与Pegasys®，ZADAXIN®或Pegasys®和ETV组合是安全和耐受性良好，并导致这是深刻的，包括抗病毒反应：消除（最多7数减少到LLOQ）的HBsAg的血液中的血清转变为HBsAg和HBeAg和，消除（最多6个对数减少到LLOQ）的血清HBV DNA。这些临床试验表明，REP 2139Ca似乎显著增加实现相比现有疗法的12个月的SVR率。
Replicor的海报展示将可在该公司的网站在发布会www.replicor.com/science/conference-presentations结束。有关2015年柳叶刀病毒性肝炎会议的更多信息：www.asianoncologysummit.com/vhep-summit.asp
关于Replicor
Replicor是一家私人持有的生物制药公司，在治疗HBV和HDV的发展的最先进的动物和人类的临床数据。该公司致力于加快有效治疗的发展与患者HBV和HBV / HDV感染。有关Replicor更多信息，请访问我们的网站www.replicor.com，并按照我们的Twitter @replicorinc。
往来
Replicor
亚历山德拉·彼得森，212-508-9709
[email protected] |
|
发表于 2015-4-11 14:00
